OTC nasal sprays reduce infection and cut antibiotic use, suggests study

Over the counter (OTC) nasal sprays can reduce the length of upper respiratory tract infection by around 20%, and cut antibiotic risk by more than a quarter, a large scale study published in The Lancet has found.

Two nasal sprays that trap, neutralise or reduce viruses in the nose or throat were compared to the impact of an online resource promoting physical activity and stress management.

Related Article: Beyond the scales: reframing eating disorder recognition in primary care

Some 13,799 adult patients from 332 GP practices, all of whom had an existing health problem or risk factor for infection, and/or recurrent respiratory infections in the past, were randomised to receive one of the three interventions, or were put into a control group to receive brief usual self-care advice.

Over a period of six months, the control group self-reported an average of 8.2 days of respiratory tract illness.

But those that used a Vicks-First-Defence gel-based nasal spray that uses a microgel to trap and neutralise viruses in the nose experienced just 6.5 days of illness on average.

And those that used a saline liquid-based nasal spray that reduces levels of virus in the nasopharynx experienced a mean of 6.4 days of illness.

Related Article: Sharp rise in diabetes cases prompts call for better postnatal support

Meanwhile, those that were directed to the online resource promoting exercise and stress management experienced 7.4 days of illness on average.

All three interventions resulted in reduced antibiotic use, reducing relative risk reduction by more than 25%, as well as reducing the number of days with more severe symptoms.

Related Article: Novo Nordisk launch new 7.2mg single-dose Wegovy pen

Paul Little, professor in primary care research from the University of Southampton, who led the trial, said: ‘Given these results, our advice, particularly for  those at higher risk from infections or those who get recurrent infections, is at the first sign of cough, sore throat, cold or flu like symptoms, use a nasal spray to prevent it from developing fully, and to use the sprays preventatively after close exposure to people with infections.’

And Dr Adam Geraghty, associate professor of psychology and behavioural medicine at the University of Southampton, who led the exercise and stress reduction part and co-led the study, said: ‘If widely used these interventions could potentially have a valuable role for reducing antibiotic use and antimicrobial resistance, and in reducing the impact of respiratory viruses for patients, the health service and the wider economy.’